The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide (Q39883308)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide |
scientific article |
Statements
1 reference
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide (English)
1 reference
Hartmut Goldschmidt
1 reference
Stefan Schmitt
1 reference
Anthony D Ho
1 reference
19 March 2010
1 reference
1 reference
33
1 reference
4
1 reference
183-186
1 reference
Identifiers
1 reference
1 reference